LONGEVITY FUNDS 2 LLC

Thesis

They invest primarily in the healthcare sector, with a strong emphasis on drug discovery and therapeutics aimed at combating age-related diseases. The firm targets Seed and Series A stage companies, predominantly in the United States, and aims to lead investments. Their strategy focuses on identifying scientifically innovative, founder-led startups with unconventional backgrounds that have a clear path to regulatory approval and scalable business models. They explicitly avoid traditional biotech patterns, repeat pharma executives without a passion for longevity, large pharma corporate structures, consumer wellness products, and lifestyle longevity services. The Longevity Fund, as a whole, has $37 million under management and expects to make 8 to 10 investments per fund, with check sizes ranging from $250,000 to $3 million. The broader Longevity Fund portfolio has collectively raised over $500 million in follow-on funding, with several programs in clinical trials. The original Longevity Fund (2011-2023) deployed approximately $100 million and achieved five IPOs.

Related lists

• Seed-stage Healthcare investors
• Series A Healthcare investors
• Seed investors based in San Francisco, CA